Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

作者：Thomas Powles, Elizabeth R. Plimack, Denis Soulières, Tom Waddell, Viktor P. Stus, Rustem Airatovich Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor O. Vynnychenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L. Rhoda Molife, Michael B. Atkins, Brian I. Rini · 发表于：The Lancet Oncology · 年份：2020 · DOI：10.1016/s1470-2045(20)30436-8 · 被引用次数：764 · 研究领域：Renal cell carcinoma treatment、Ferroptosis and cancer prognosis、Cancer Immunotherapy and Biomarkers